Clinical trials: Busulfan, open to volunteers
Hematologic Neoplasms
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high.
- Trial name
- NCT05327023
- Testing
- donor lymphocyte infusion, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Acute Leukemia, Acute Myeloid Leukemia
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections.
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia
- Trial name
- NCT03810196
- Testing
- CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Children's Hospital of Philadelphia
AML, Adult
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR
A multicenter, randomized, controlled clinical study comparing the efficacy and safety of allogeneic hematopoietic stem cell transplantation with decitabine-Fludarabine- busulfan (Dec-FB4) and Fludarabine-busulfan (FB4) as…
- Trial name
- NCT06297772
- Testing
- Decitabine, Fludarabine Injection, Busulfan Injection
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Ruijin Hospital
Severe Combined Immunodeficiency
Autologous Gene Therapy for Artemis-Deficient SCID
This study aims to determine if a new method can be used to treat Artemis-deficient Severe Combined Immunodeficiency (ART-SCID), a severe form of primary immunodeficiency caused by mutations in the DCLRE1C gene.
- Trial name
- NCT03538899
- Testing
- AProArt-CD34, CliniMACS® CD34 Reagent System cell sorter device, Busulfan
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
B-cell Acute Lymphoblastic Leukemia
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before…
- Trial name
- NCT03509961
- Testing
- NGS-MRD, Myeloablative allogeneic HCT with a non-TBI conditioning regimen
- Where
- 24 sites in United States
- Volunteers
- 95 people
- Sponsor
- Pediatric Transplantation & Cellular Therapy Consortium
T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients
T-cell acute lymphoblastic leukemia (T-ALL), a hematological malignant neoplasm of immature T cells, accounting for a morbidity of 10-15% among pediatric and 20-25% among adult patients of ALL.
- Conditions
- T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Total Body Irradiation, Chemotherapy
- Trial name
- NCT06673459
- Testing
- TBICy, BuCy
- Where
- China
- Volunteers
- 430 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Graft Failure, Sickle Cell Disease
Allo HSCT for High Risk Hemoglobinopathies
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation…
- Conditions
- Graft Failure, Sickle Cell Disease, Hemoglobinopathies
- Trial name
- NCT06872333
- Testing
- Alemtuzumab, Total Body Irradiation, Cell Infusion
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Subjects Treated With Busulfan
Busulfan Sample Collection Study
Busulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT05711732
- Testing
- MyCare Oncology Busulfan Assay Kit
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Saladax Biomedical, Inc.
Acute Leukemia, Immune Deficiency Disorder
Umbilical Cord Blood Transplantation From Unrelated Donors
This study is being done to determine how long it takes for the engraftment (recovery of blood cell counts) of umbilical cord stem cells and also how often engraftment of umbilical cord stem cells transplanted from an unrelated…
- Conditions
- Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder, Metabolism Disorder
- Trial name
- NCT03016806
- Testing
- Total Body Irradiation 1200 cGy, Total Body Irradiation 200 cGy, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Acute Leukemia, Acute Myeloid Leukemia
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further…
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma
- Trial name
- NCT03314974
- Testing
- HSCT with TBI Regimen, HSCT with Non-TBI Regimen
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Myelofibrosis
Haplo-HSCT for Myelofibrosis
Myelofibrosis (MF) is a myeloproliferative neoplasm causing bone marrow failure and high risk of leukemia transformation. JAK2 inhibitors improve symptoms but do not cure MF.
- Trial name
- HHM (NCT06674382)
- Testing
- Haploidentical hematopoietic stem cell transplantation
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Peking University People's Hospital
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
This study was designed as a prospective, multicenter, open-label, randomized controlled trial. Eligible participants were patients aged 15-60 years with high-risk or relapsed/refractory acute myeloid leukemia (AML), acute…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell
- Trial name
- NCT07562568
- Testing
- SHR2554/AZA + Overlapped TBF, mBUCY conditioning regimen
- Where
- China
- Volunteers
- 160 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Transfusion Dependent Beta-Thalassemia
A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
This is a single-arm, open label, single-dose study in subjects with transfusion dependent β-thalassaemia. The study will evaluate the safety and efficacy of autologous CD34+ Human Hematopoietic Stem Cells that was transduced…
- Trial name
- NCT05762510
- Testing
- GMCN-508B (LentiRed)
- Where
- China
- Volunteers
- 5 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma.
- Conditions
- Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
- Trial name
- NCT03126916
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- 164 sites in United States, Canada and 1 more
- Volunteers
- 750 people
- Sponsor
- Children's Oncology Group
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
Background: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies.
- Conditions
- Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases, Common Variable Immunodeficiency
- Trial name
- NCT04339777
- Testing
- Busulfan test dose, Fludarabine, Busulfan
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Busulfan Pharmacokinetic Analysis, Busulfan Dosing
26DT052; Scaling Busulfan Dose to Body Surface Area in Children
The goal of this pilot study is to determine if scaling the first busulfan dose to Body Surface Area (BSA) in children with a BSA ≥0.5 m2 and using a BSA-banded dosing table for infants (BSA <0.5 m2) increases the fraction of…
- Conditions
- Busulfan Pharmacokinetic Analysis, Busulfan Dosing, Hematopoietic Stem Cell Transplant (HSCT), Busulfan
- Trial name
- NCT07792369
- Testing
- Busulfan (BU)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Children's Hospital of Philadelphia
Aplastic Anaemia
A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
Aplastic anemia (AA) is a bone marrow failure disorder characterized by pancytopenia and hypoplastic bone marrow caused by the decrease of hematopoietic stem cells.
- Trial name
- NCT07499284
- Testing
- Haploidentical hematopoietic cell transplantation combined with unrelated cord blood stem cells, Haploidentical hematopoietic cell transplantation
- Where
- 4 sites in China
- Volunteers
- 224 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Hemoglobinopathy, Sickle Cell Disease
A Long-term Follow-up Study in Patients Who Received BEAM-101
This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing…
- Trial name
- NCT07373639
- Testing
- Long-Term Follow-up Study of patients who received BEAM-101
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Beam Therapeutics Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
This project is a prospective, single-center, randomized controlled clinical study. The subjects were high-risk or relapsed/refractory AML or ALL patients aged ≤ 65 years diagnosed by bone marrow cell morphology, immunology…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell, Conditioning Therapy
- Trial name
- NCT06816134
- Testing
- TmBU conditioning Regimen, mBUCY conditioning regimen
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Relapsed or Refractory Acute Myeloid Leukemia
A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML
Acute myeloid leukemia (AML) is one of the hematologic malignancies, for which patients typically undergo chemotherapy to achieve complete remission.
- Trial name
- NCT06879847
- Testing
- Salvage Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University